You are here:

MS Decisions

In the UK, there are now 14 disease modifying drugs (DMDs) that are approved for use in the NHS for people with relapsing remitting MS (RRMS). Each drug offers a different combination of benefits and risks. MS Decisions can help you make your choice.

You might be coming to MS Decisions because:

  • you want a general introduction to the range of DMDs that can be prescribed for RRMS so that you can get familiar with your treatment options.
  • you have seen your neurologist or MS nurse and you want to know what to expect and what you need to consider if starting DMD treatment.
  • your neurologist has given you specific options to consider and you want to compare these DMDs so that you can go to your next clinic visit with your own thoughts and questions.
  • you are already on a DMD and you are considering switching to another one.

Whatever your situation, MS Decisions can help you by providing reliable information about DMDs for RRMS in a format that makes it easy to compare them.

MS Decisions was highly commended in the 2016 BMA Patient Information Awards. The award reviewers described the guide as:

an excellent resource that will help many people through a difficult decision.

Girl in front of grey background with two speech bubbles with questions saying what type of drug? and how often do I need to take it?

Compare Disease Modifying Drugs (DMDs)

Use our MS Decisions aid to help filter and compare Disease Modifying Drugs (DMDs) that can be prescribed in the UK for RRMS.

Find out who can take each drug, the possible side effects and monitoring that might be needed.

Use DMD decision aid tool
Guide to decision making

Guide to decision making

This guide will help you think through the issues that are involved in choosing a disease modifying drug. It discusses some of the pros and cons of treatment, as well as considering how family and work might affect your decision.

About MS Decisions

About MS Decisions

MS Decisions was established in 2004 as an independent source of reliable, evidence-based information about the disease modifying drugs for relapsing remitting MS.